We are proud to announce that the submissions for an oral and two poster presentations of our CEO, Attila Bérces, were accepted for the upcoming 27th annual EFI European Immunogenetics and Histocompatibility Conference in Maastricht, The Netherlands.

After several conferences this year, there is a new chance for showing what we do with Omixon Target and how it can be useful in cancer research, HLA typing and many other fields of medicine and science.

We plan to publish updates during the conference as well!